In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 12, 1996, Pages 2894-2897

  Yagel, Susan K ^a   Barrett, John F ^a   Amaratunga, Dhammika J ^a   Frosco, Mary Beth ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPTICEMIA;

EID: 0029826961     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.12.2894     Document Type: Article

References (23)

1. Burwen, D. R., S. N. Banerjee, R. P. Gaynes, and the National Nosocomial Infections Surveillance System. 1994. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J. Infect. Dis. 170: 1622-1625.
2. Chidiac, C., M. Roussel-Delvallez, B. Guery, and G. Beaucaire. 1995. Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia. Antimicrob. Agents Chemother. 39:677-679.
3. Cleeland, R., and E. Squires. 1991. Evaluation of new antimicrobials in vitro and in experimental animal infections, p. 739-784. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore.
4. Collett, D. 1991. Modelling binary data. Chapman and Hall, London.
5. Davis, R., and H. M. Bryson. 1994. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47:677-700.
6. Dudley, M. N., J. Blaser, D. Gilbert, K. H. Mayer, and S. H. Zinner. 1991. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J. Infect. Dis. 164:499-506.
7. Fernandes, P. B., R. N. Swanson, D. J. Hardy, C. W. Hanson, L. Coen, R. R. Rasmussen, and R. H. Chen. 1989. Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. J. Antibiot. XLII:521-526.
8. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barrett, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
9. Furuya, N., Y. Hirakata, K. Tomono, T. Matsumoto, K. Tateda, M. Kaku, and K. Yamaguchi. 1993. Mortality rates amongst mice with endogenous septicaemia caused by Pseudomonas aeruginosa isolates from various clinical sources. J. Med. Microbiol. 39:141-146.
10. Gargolla-Viola, D., M. Esteve, S. Llovera, and X. Roca. 1991. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob. Agents. Chemother. 35:442-447.
11. Goto, S., and S. Miyazaki. 1992. New quinolones. In vivo antibacterial activity. Prog. Drug Res. 38:29-37.
12. Goto, S., S. Miyazaki, and Y. Ishida. 1992. In vitro and in vivo antibacterial activities of levofloxacin (DR-3355), a new quinolone antibacterial. Chemotherapy (Tokyo) 40:14-25.
13. Grundmann, H., A. Kropec, D. Hartung, R. Berner, and F. Daschner. 1993. Pseudomonas aeruginosa in a neonatal intensive care unit: reservoirs and ecology of the nosocomial pathogen. J. Infect. Dis. 168:943-947.
14. Hancock, R. E. W. 1991. Bacterial outer membranes: evolving concepts. ASM News 57:175-182.
15. Kiesel, N., K. H. Geweniger, P. Koletzki, D. Isert, M. Limbert, A. Markus, G. Riess, H. Schramm, and P. Iyer. 1995. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J. Antimicrob. Chemother. 35:805-819.
16. Makhoul, I. R., D. Merzbach, C. Lichtig, and M. Berant. 1993. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration. J. Infect. Dis. 168: 1296-1299.
17. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed. NCCLS document M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
18. Richard, P., R. Le Floch, C. Chamoux, M. Pannier, E. Espaze, and H. Richet. 1994. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J. Infect. Dis. 170:377-383.
19. Römling, U., B. Fiedler, J. Boßhammer, D. Grothues, J. Greipel, H. von der Hardt, and B. Tümmler. 1994. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J. Infect. Dis. 170:1616-1621.
20. Tanaka, M., M. Otsuki, T. Une, and T. Nishino. 1990. In vitro and in vivo activity of DR-3355, an optically active isomer of ofloxacin. J. Antimicrob. Chemother. 26:659-666.
21. Walker, R. C., and A. J. Wright. 1991. The fluoroquinolones. Symposium on antimicrobial agents - part IV. Mayo Clin. Proc. 66:1249-1259.
22. Wood, C. 1993. Quinolone resistance: a practical perspective. Arch. Intern. Med. 153:120. (Letter.)
23. Yoshida, T., T. Muratani, S. Iyobe, and S. Mitsuhashi. 1994. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:1466-1469.